(StatePoint) According to the American Cancer Society, the number of women in the United States with a history of invasive breast cancer is estimated to be 3.1 million as of January 2023, rising 12% to 4 million by 2024. Expected.
Breast cancer is highly treatable if detected early, with a 99% five-year survival rate when cancer is found in breast tissue only. However, if the cancer spreads to the lymph nodes or nearby tissues in the armpit (locoregional stage), the 5-year survival rate drops to 85%, and if it spreads to other lymph nodes or parts of the body (long-stage or long-stage). , the 5-year survival rate drops to 27% for metastatic cancer. These figures suggest a significant need for more effective treatments for this deadly cancer.
New immunotherapies may offer a solution for patients with advanced breast cancer who have fewer treatment options. BriaCell Therapeutics (NASDAQ: BCTX)’s Bria-IMT and Bria-OTS, currently in development, are two agents that have shown promising results in clinical trials so far, and have been demonstrated in multiple patients, including those with metastatic disease. shows significant tumor regression. Both drugs work through an entirely new therapeutic mechanism, utilizing breast cancer cells to generate a potent immune response against breast cancer.
“Chemotherapy is the only option left for many breast cancer patients. We recognize that these can cause serious, sometimes fatal infections, and immunotherapy has recently emerged as a type of treatment that avoids most of these side effects. Unfortunately, immunotherapy is currently only effective in a subset of patients and only when combined with chemotherapy.We have the potential to bring significant benefits to more patients with few side effects. We are dedicated to the development of new immunotherapeutic approaches that are more effective and more effective, and our efforts will enable these patients to be much better tolerated, improve their quality of life and extend their survival. We hope to provide another option,” said Dr. William Williams, CEO of BriaCell Therapeutics.
In the case of Bria-OTS, a simple saliva test can determine a patient’s cell type, allowing personalized immunotherapy treatment. Dr. Williams said the technology is already being investigated for other cancer treatment applications, including prostate cancer, lung cancer and melanoma. To learn more about the future of cancer care, please visit: briacell.com/about-briacell.
Breast cancer is the second leading cause of cancer death in American women. Thankfully, the arrival of drugs in the near future could change the way we think about treating the disease, especially in the later stages, and bring new hope to patients.
